{
    "clinical_study": {
        "@rank": "124354", 
        "acronym": "ALTN/MTC", 
        "arm_group": {
            "arm_group_label": "Anlotinib Hydrochloric Capsule", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Anlotibib (ALTN) is a kind of innovative medicines approved by State Food and Drug\n      Administration\uff08SFDA\uff09 which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co.,\n      Ltd. ALTN is a kinase inhibitor of receptor tyrosine with multi-targets, especially for\n      VEGFR2 and VEGFR3. It has the obvious resistance to new angiogenesis. The trial is to\n      explore ALTN for the effectiveness of advanced medullary thyroid carcinoma and security."
        }, 
        "brief_title": "A Phase II Study of Anlotinib Hydrochloric Capsule in MTC Patients", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Tumor", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1.late  medullary thyroid carcinoma; 2.18-70years, ECOG:0-2,Expected survival period\n             >3 months; 3.Calcitonic\u2265500pg/ml, thyroid function normal; 4.HB\u2265100g/L,ANC(Absolute\n             Neutrophil Count) \u22651.5\u00d7109/L\uff1bPLT\n\n               -  80\u00d7109/L ,BIL/Cr in normal range,ALT/AST(aspartate aminotransferase\n                  )\u22641.5*ULN(for hepatic metastases,ALT/AST(aspartate aminotransferase )\u22645*ULN)\n                  ;TG\u2264 3.0mmol/L\uff0ccholesterol\u22647.75mmol/L; LVEF\n\n               -  LLN. 5.Username contraceptive during the study and after 6 months; 6.Volunteer.\n\n        Exclusion Criteria:\n\n          -  1.Received vascular endothelial growth inhibitor type of targeted therapy; 2.Subject\n             was diagnosed with The second cancer; 3.Participated in other clinical trials in four\n             weeks; 4.Received in other radiotherapy or chemotherapy treatment in four weeks;\n             5.With AE> 1; 6.Has influence of oral drugs; 7.Brain metastases, spinal cord\n             compression, cancerous meningitis, or the brain/soft meningeal disease patient; 8.Any\n             serious or failed to control the disease 9.Artery/venous thrombotic; 10.Coagulant\n             function abnormality; 11.Arteriovenous thrombosis event; 12.History of psychiatric\n             drugs abuse or a mental disorder; 13.Immunodeficiency history; 14.Concomitant\n             diseases."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "47", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01874873", 
            "org_study_id": "ALTN-01-IIA"
        }, 
        "intervention": {
            "arm_group_label": "Anlotinib Hydrochloric Capsule", 
            "intervention_name": "Anlotinib Hydrochloric Capsule", 
            "intervention_type": "Drug", 
            "other_name": "ALTN"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 15, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Yihebali Chi, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100021"
                    }, 
                    "name": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
                }, 
                "investigator": [
                    {
                        "last_name": "Yongkun Sun, doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Zhengjiang Li, doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jianchun Yu, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "Peking Union Medical College Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Weiming Kang, doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Zhiqing Ma, doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Xiangjin Chen, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Fuzhou", 
                        "country": "China", 
                        "state": "Fujian"
                    }, 
                    "name": "The first hospital affiliated to fujian medical university"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jun Wang, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Lanzhou", 
                        "country": "China", 
                        "state": "Gansu"
                    }, 
                    "name": "Gansu Province Tumor Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Zhuming Gou, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Guozhou", 
                        "country": "China", 
                        "state": "Guangdong"
                    }, 
                    "name": "Sun Yat-Sen University Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jiewu Zhang, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Harbin", 
                        "country": "China", 
                        "state": "Heilongjiang"
                    }, 
                    "name": "Harbin medical university affiliated tumor hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Yuan Zhang, Doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "state": "Jiangsu"
                    }, 
                    "name": "Jiangsu province tumor hospital"
                }, 
                "investigator": {
                    "last_name": "Fangzhou Liu, doctor", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Zhendong Li, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China", 
                        "state": "Liaoning"
                    }, 
                    "name": "Liaoning Province Tumor Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Yu Wang, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "state": "Shanghai"
                    }, 
                    "name": "Cancer Hospital of Fudan University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ming Gao, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "state": "Tianjin"
                    }, 
                    "name": "Tianjin Medical University Cancer Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Yang Yu, doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Xundong Wang, doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 2 Study of Anlotinib Hydrochloric Capsule in Advanced Medullary Thyroid Carcinoma", 
        "overall_contact": {
            "last_name": "Jinwan Wang, doctor", 
            "phone": "010-87788842"
        }, 
        "overall_official": [
            {
                "affiliation": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences", 
                "last_name": "Jinwan Wang, doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences", 
                "last_name": "Pingzhang Tang, doctor", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "enhanced CT scan", 
            "safety_issue": "No", 
            "time_frame": "each 42 days up to 48 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01874873"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "each 21 days up to  up to 48 months"
        }, 
        "source": "Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}